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This study describes a method for increasing the immunogenicity of influenza virus vaccines by exploiting the
natural anti-Gal antibody to effectively target vaccines to antigen-presenting cells (APC). This method is based on
enzymatic engineering of carbohydrate chains on virus envelope hemagglutinin to carry the -Gal epitope (Gal1-
3Gal1-4GlcNAc-R). This epitope interacts with anti-Gal, the most abundant antibody in humans (1% of immu-
noglobulins). Influenza virus vaccine expressing -Gal epitopes is opsonized in situ by anti-Gal immunoglobulin G.
The Fc portion of opsonizing anti-Gal interacts with Fc receptors on APC and induces effective uptake of the
vaccine virus by APC. APC internalizes the opsonized virus to transport it to draining lymph nodes for stimulation
of influenza virus-specific T cells, thereby eliciting a protective immune response. The efficacy of such an influenza
vaccine was demonstrated in 1,3galactosyltransferase (1,3GT) knockout mice, which produce anti-Gal, using the
influenza virus strain A/Puerto Rico/8/34-H1N1 (PR8). Synthesis of -Gal epitopes on carbohydrate chains of PR8
virus (PR8gal) was catalyzed by recombinant 1,3GT, the glycosylation enzyme that synthesizes -Gal epitopes in
cells of nonprimatemammals.Mice immunized with PR8gal displayedmuch higher numbers of PR8-specific CD8

and CD4 T cells (determined by intracellular cytokine staining and enzyme-linked immunospot assay) and
produced anti-PR8 antibodies with much higher titers than mice immunized with PR8 lacking -Gal epitopes. Mice
immunized with PR8gal also displayed a much higher level of protection than PR8 immunized mice after being
challenged with lethal doses of live PR8 virus. We suggest that a similar method for increasing immunogenicity may
be applicable to avian influenza vaccines.
The increased risk of an influenza pandemic raises the need for
the generation of effective vaccines that will elicit both humoral
and cellular immune responses for prevention of infection in the
respiratory tract and destruction of virus-infected cells in the
body. A prerequisite for the efficacy of any influenza vaccine is its
effective uptake at the vaccination site by antigen-presenting cells
(APC) such as dendritic cells (DC) and macrophages (46). This
applies to vaccines that are comprised of inactivated virus, subunit
hemagglutinin (HA) vaccine, or a recombinant protein such as
HA (7, 45). APC internalize the vaccine and transport it to drain-
ing lymph nodes, where they present the immunogenic viral pep-
tides on cell surface major histocompatibility complex class I
(MHC-I) and class II molecules for activation of virus-specific
CD8 and CD4 T cells, respectively (46). Activated CD8 T
cells become cytotoxic T lymphocytes (CTL), which destroy in-
fected cells, and activated CD4 T cells, help virus-specific B cells
to produce antiviral antibodies and CD8 T cells to become CTL.
Since the currently used influenza vaccines lack markers that
identify them as molecules or particulate material that have to be
internalized by APC, the uptake of these vaccines is likely to be
suboptimal and to be mediated only by random endocytosis. The
suboptimal efficacy of influenza vaccines is further suggested by
the finding that in immunized populations, particularly the el-
derly, 25% to 50% of individuals may contract the disease during
the flu season (7, 25, 45).
Targeting of vaccines to APC can be achieved by opsonizing
them (i.e., forming immune complexes) with the corresponding
immunoglobulin G (IgG) molecules. This targeting occurs be-
cause APC, including DC, Langerhans cells of the skin, and
macrophages, all express Fc receptors (FcR) for the Fc
portion of the antigen-bound IgG antibodies (5, 31, 33, 35, 43).
The interaction between the Fc portion of the opsonizing an-
tibodies and FcR on APC is considered the most effective
mechanism by which APC identify and internalize antigens
that should be targeted for an effective immune response (5).
Accordingly, administration of antigens in the form of immune
complexes with various antigens, including tetanus toxoid (9,
31), hepatitis B antigen (3), Eastern equine encephalomyelitis
virus (23), and simian immunodeficiency virus (44), increases
immunogenicity by 10- to 1,000-fold. We proposed to exploit
the natural anti-Gal antibody, which is present in all humans as
1% of IgG, for such targeting of influenza virus vaccines to
APC. We developed a method for in situ formation of immune
complexes between influenza vaccines and the natural anti-Gal
antibody, thereby achieving effective targeting of viral vaccines
to APC.
Anti-Gal is the most abundant natural antibody in humans,
constituting 1% of serum IgG (17). This antibody interacts
specifically with the -Gal epitope (Gal1-3Gal1-4GlcNAc-R)
on glycolipids and glycoproteins (10, 12, 15). Anti-Gal is produced
throughout life as a result of antigenic stimulation by bacteria
of the gastrointestinal flora (16). The -Gal epitope is absent
in humans but is synthesized by the glycosylation enzyme
1,3galactosyltransferase (1,3GT) in very large amounts in
cells of nonprimate mammals, prosimians, and New World
monkeys (13, 19). The 1,3GT gene was inactivated in ances-
tral Old World primates (19, 20, 24, 27, 28, 29); thus, humans,
apes, and Old World monkeys all lack -Gal epitopes but
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produce the anti-Gal antibody in large amounts (11, 13, 19). If
cells, viruses, or molecules expressing -Gal epitopes are in-
troduced into humans or Old World monkeys, anti-Gal binds
avidly in vivo to these epitopes. This is indicated in xenotrans-
plantation, in which in vivo binding of anti-Gal to -Gal
epitopes on transplanted pig hearts or kidneys is the main
cause of the rapid rejection of such grafts in humans and Old
World monkeys (6, 11, 21, 34). This in situ interaction of
anti-Gal with -Gal epitopes may be exploited for targeting
viral vaccines expressing -Gal epitopes to APC. In fact, anti-
Gal is the only antibody in humans that can serve the purpose
of targeting antigens to APC, because it is the only natural
antibody known to be produced ubiquitously in large amounts
in humans (10, 17). Therefore, any particulate or soluble an-
tigen that has -Gal epitopes will form immune complexes
with anti-Gal and will be targeted for effective uptake by APC
(1, 8, 18, 30).
In a recent study using a unique model of 1,3GT knockout
mice, we showed that the recombinant gp120 protein of the
human immunodeficiency virus envelope increases its immu-
nogenicity by 100-fold if the vaccine protein is engineered to
express -Gal epitopes (1). This increased immunogenicity is
achieved because of the in vivo formation of immune com-
plexes between anti-Gal and the vaccinating gp120 expressing
the -Gal epitopes. We found that we could synthesize multi-
ple -Gal epitopes on the N-linked carbohydrate chains of
gp120 by using recombinant 1,3GT that we produced in the
Pichia pastoris yeast expression system (4). This observation
raised the question of whether increasing immunogenicity by
anti-Gal-mediated targeting to APC may also be achieved by
using intact, inactivated influenza virus engineered to express
multiple -Gal epitopes in a vaccine.
The HA molecule on the envelope of influenza virus is a
glycoprotein with seven carbohydrate chains capped with N-
acetyllactosamines (Gal1-4GlcNAc-R) (26, 32) on which
-Gal epitopes can be synthesized by using recombinant
1,3GT (22). We hypothesized that the synthesis of -Gal
epitopes on inactivated influenza virus and subsequent immu-
nization with inactivated influenza virus expressing -Gal
epitopes would result in a significantly higher level of immune
response than that measured following immunization with un-
processed inactivated influenza virus that lacks -Gal epitopes.
Such a difference in the immune response would be associated
with anti-Gal-mediated targeting of the vaccine virus express-
ing -Gal epitopes to APC and would result in differential
protection against challenge with the live virus.
The only available nonprimate mammalian experimental
model which produces anti-Gal and thus enables analysis of
immunogenicity of anti-Gal opsonized vaccines is the 1,3GT
gene knockout (KO) mouse, in which the 1,3GT gene was
disrupted by targeted insertion of the neomycin resistance
gene (41, 42). This mouse mimics the relevant human immune
characteristics, as it lacks -Gal epitopes and can produce
anti-Gal as well as humans (1, 8, 30, 39, 40). In contrast, other
nonprimate mammals (e.g., wild-type mice, rats, rabbits, fer-
rets, etc.) express -Gal epitopes on their cells and thus are
immunotolerant to this epitope and cannot produce anti-Gal
(13, 19, 39). The characteristics of anti-Gal produced in KO
mice are similar to those in humans (1). We studied the im-
mune response to the A/Puerto Rico/8/34- H1N1 (PR8) influ-
enza virus strain in these KO mice. As described below, we
found that vaccine containing inactivated PR8 virus processed
to express -Gal epitopes (PR8gal) is much more immuno-
genic than the unprocessed inactivated virus.
MATERIALS AND METHODS
Supplies. The recombinant glycosylation enzyme 1,3galactosyltransferase
(1,3GT) was produced in the expression system of Pichia pastoris as previously
described (4). The monoclonal anti-Gal antibody (designated M86) was obtained
in tissue culture supernatants of hybridoma M86 cells, as previously described
(14). Horseradish-peroxidase (HRP)-conjugated anti-mouse IgG and anti-mouse
IgA antibodies were purchased from Accurate Laboratories (Westbury, NY).
The glycoprotein comprised of synthetic -Gal epitopes linked to bovine serum
albumin (-Gal BSA) was purchased from Dextra Laboratories (Reading,
United Kingdom). Mouse anti-Gal was isolated from the sera of KO mice that
were repeatedly immunized with pig kidney membrane homogenate in order to
elicit production of anti-Gal, as previously described (1). The antibody was
isolated from the sera by affinity columns of synthetic -Gal epitopes linked to
silica beads (Synsorb, Alberta, Canada) (12, 13). The Ribi adjuvant, trehalose
dicorynomycolate, was purchased from Corixa (Hamilton, MT).
Virus preparation and inactivation. Influenza virus strain A/PR/8/34 (H1N1)
(PR8 virus) was propagated, as we previously described, in the allantoic cavity of
11-day-old embryonated chicken eggs (18, 22). The virus was precipitated from
the allantoic fluid by polyethylene glycol and purified on a continuous sucrose
gradient as previously described (37). The protein concentration was measured
by color reaction, using a Pierce bicinchoninic acid protein assay (Pierce, Rock-
ford, IL). Virus titers were measured by a hemagglutination assay with chicken
red blood cells (ChRBC; Lampire Biological Laboratories, Inc., Pipersville, PA)
and by a plaque-forming assay with MDCK cells.
Viruses were inactivated by incubation for 45 min at 65°C. Prior to immuni-
zation, the efficacy of the inactivation was confirmed by the complete loss of
hemagglutinating activity by influenza viruses incubated with ChRBC, even at a
concentration corresponding to 104 hemagglutinating units (HAU)/ml.
Mice and immunization procedures. The mice used were 1,3GT KO mice on
an H-2b genetic background (42), which were bred and maintained at the animal
facility of the University of Massachusetts Medical Center. These mice lack
-Gal epitopes and thus are not immunotolerant to it and can produce the
anti-Gal antibody (1, 8, 30, 39, 40). In contrast, the wild-type (WT) mouse
counterpart (C57BL/6) expresses -Gal epitopes on its cells and cannot produce
anti-Gal (39). Experiments were performed with both males and females and
found to yield similar results. All experiments with mice were performed accord-
ing to AAALAC guidelines. The mice were immunized intraperitoneally 3 to 4
times with 50 mg pig kidney membrane homogenate to induce anti-Gal produc-
tion at titers similar to those in humans (titers of 1:200 to 1:2,000, as measured
by enzyme-linked immunosorbent assay [ELISA] with -Gal BSA used as a
solid-phase antigen) (1). Following demonstration of anti-Gal IgG production,
the mice received a subcutaneous injection (1 g in Ribi adjuvant) of inactivated
PR8 or inactivated PR8 influenza virus that was enzymatically engineered to
express -Gal epitopes (PR8gal virus). The injection was repeated after 2 weeks.
Both antibody and cellular immune responses were evaluated 14 days after the
second injection.
Enzymatic engineering of PR8 to express -Gal epitopes. The enzymatic
reaction to synthesize -Gal epitopes on PR8 viruses was performed in an
enzyme buffer containing 0.1 M MES (methylethyl morpholino sulfonate; pH
6.0) and 25 mM MnCl2, as previously described (1, 22). -Gal epitopes were
synthesized on PR8 (100 g/ml) by recombinant 1,3GT (30 g/ml) and UDP-
Gal (1 mM) for 2 h at 37°C. The control PR8 virus was incubated under similar
conditions with inactivated 1,3GT and 1 mM UDP-Gal. Inactivation of 1,3GT
was achieved by incubating the enzyme for 10 min in boiling water.
Western blotting and silver-staining analyses. PR8 virus was run under de-
naturing and reducing conditions on sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and tested for binding with purified mouse anti-Gal or mono-
clonal anti-Gal M86 antibodies. Viral proteins were separated on 10% precast
polyacrylamide gel (NuSep, Australia) for 2 h at 100 V. The proteins were then
transferred to polyvinylidene difluoride membranes by electroblotting and
blocked overnight in a solution containing 1% fat-free milk powder. The mem-
branes were then incubated in either mouse anti-Gal or monoclonal M86 anti-
bodies in 1% BSA for 2 h at room temperature, followed by four washes for 15
min each in Tween-PBS. The anti-Gal blots were incubated with HRP-conju-
gated goat anti-mouse IgG (for mouse anti-Gal) or goat anti-mouse IgM (for
M86) antibodies (Accurate Chemical & Scientific, NY) diluted 1:500 for 1 h at
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room temperature and washed as described above. Subsequently, the mem-
branes were exposed to diamino benzidine (Sigma) until the staining developed.
For silver staining, the gel was fixed with 100 ml of fixing solution (50% ethanol–
10% acetic acid in ultra-pure water). After 40 min, the gel was washed with 30%
ethanol, and then a ProteoSilver stain kit (Sigma) was used according to the
manufacturer’s protocol.
ELISA assays. Anti-Gal titers in mice immunized with pig kidney membrane
and the level of production of anti-PR8 antibodies were determined by ELISA as
previously described (1). Briefly, ELISA wells were coated with -Gal BSA (10
g/ml) or PR8 virus (1 g/ml) overnight at 4°C. The plates were washed once
with PBS and blocked with 1% BSA in PBS. Serum samples at various dilutions
(50-l aliquots) were plated in the wells for 2 h at room temperature. After the
plates were washed, HRP-coupled goat anti-mouse IgG or goat anti-mouse IgA
was added for 1 h. Color reactions were developed with ortho-phenylene di-
amine, and absorbance was measured at 492 nm. In assays using the monoclonal
anti-Gal antibody M86 (14), HRP-anti-mouse IgM was used as a secondary
antibody. For antibody analysis within the sera, the first dilution was 1:10,
whereas for analysis of the supernatants of lung homogenates, the first dilution
was 1:1.
HI assay. The ability of anti-HA antibodies to inhibit viral agglutination of
ChRBC was measured as described previously (18). Briefly, 5 HAU/ml of PR8
virus was plated in 96-well V-bottom plates (Corning). Sera were diluted in PBS
containing 0.08% sodium azide. Aliquots of sera at serial twofold dilutions
(beginning with a serum dilution of 1:10) were added to the virus and incubated
overnight at 4°C. Subsequently, 50 l of 1% ChRBC suspension was added and
incubated for 30 min at room temperature. HA inhibition (HI) titers were
determined as the highest serum dilution at which the hemagglutination of
ChRBC was inhibited.
APC for ELISPOT and intracellular-cytokine-staining assays. The dendritic
cell line DC2.4 (36) used in this study was a gift from K. Rock (University of
Massachusetts Medical Center, Worcester, MA). These cells were pulsed with 10
g (4  103 HAU) of heat-inactivated PR8 virus overnight to allow protein
processing. The cells were then washed three times with PBS and used for
enzyme-linked immunospot (ELISPOT) or intracellular-cytokine-staining (ICS)
assays.
IFN- ELISPOT assay. ELISPOT assays for gamma interferon (IFN-)-se-
creting cells were performed with a commercial kit (Mabtech, OH) according to
the manufacturer’s protocol, as we described previously (1). Briefly, 96-well
ELISPOT plates were coated with 100 l/well of the anti-IFN- monoclonal
antibody AN18 overnight at 4°C. The plates were washed with PBS and blocked
with PBS containing 10% fetal calf serum for 30 min at room temperature.
Freshly isolated splenocytes (2  105 cells per well) were plated in triplicate
together with 2  104 cells of the dendritic cell line DC2.4 that were prepulsed
by incubation with inactivated PR8 virus as described above. After being incu-
bated overnight at 37°C in 5% CO2, the cells were removed by washing with PBS,
and aliquots of 100 l of anti-IFN-–biotin (monoclonal antibody R4-6A2;
Mabtech) were added to each well for 2 h at room temperature. The plates were
then washed with PBS, 100 l of streptavidin-alkaline phosphatase was added
per well, and the plates were incubated for 1 h at room temperature. After a
washing with PBS, 100 l of chromogenic substrate (NBT-plus; Mabtech) was
added to each well for 15 min to allow color development and the formation of
spots. The color reaction was stopped by the addition of water. The wells were
then air dried, and the spots were counted with an ELISPOT automated reader
system (performed by Zellnet, Fort Lee, NJ). Calculated frequencies were based
on the averages of the results for triplicate wells. The results were expressed as
the numbers of PR8-specific IFN--secreting T cells per 106 splenocytes.
ICS for determining T-cell activation. For ICS, the spleens from six mice/
group were harvested, and the splenocytes were adjusted to 2 106 cells per tube
for each mouse. Spleen lymphocytes were incubated at 37°C in 5% CO2 with 2
104 nonpulsed cells of the dendritic cell line DC.2.4 or DC.2.4 cells pulsed by
preincubation with heat-inactivated PR8 virus, as described above for the
ELISPOT studies. Recombinant human interleukin-2 (10 unit/ml) was added to
all samples, and after 1 h of culture, 1 l/ml of brefeldin A (10 g/ml; Sigma
Chemical Co., St. Louis, MO) was added to impair secretion of cytokines. After
another 5 h of incubation, the cells were washed once in 2% fetal calf serum–PBS
and kept overnight at 4°C. The following day, these cells were stained for surface
markers and intracellular cytokines as described by Bottrel et al. (2). Briefly,
cultured cells were stained for surface markers by incubation for 30 min on ice,
using fluorescein isothiocyanate-labeled anti-CD3 and peridinin-chlorophyll-
protein-labeled anti-CD8 or phycoerythrin-labeled anti-CD4 monoclonal anti-
bodies (BD Pharmingen, CA), followed by two washes and fixation, using solu-
tion A (Fix & Perm kit; Caltag Laboratories). These cells were washed and
permeabilized, using solution B (Fix & Perm kit; Caltag Laboratories), and
stained with APC-labeled anti-IFN- (BD Pharmingen, CA). After 20 min, the
cells were washed and resuspended in 2% paraformaldehyde. A minimum of
50,000 splenocyte-gated events were acquired using a lymphocyte gate and were
determined by size and granularity profiles. The data were analyzed by
CELLQuest software (Becton Dickinson, San Jose, CA). Antigen-specific cells
were defined as CD3CD8 or CD3CD4 T lymphocytes that coexpressed
IFN-.
Challenging mice with live PR8 virus. Mice immunized with PR8gal or with
PR8 were challenged intranasally with a dose of 2,000 PFU of PR8 virus in a
50-l solution applied to the nostrils of anesthetized mice. The mice infected
with PR8 were monitored for survival for 30 days postchallenge. In separate
studies, mice immunized with PR8gal or PR8 were euthanized 3 days postchal-
lenge, and their lungs were harvested and homogenized in PBS to a total volume
of 1 ml. The supernatants of the homogenates were subjected to analysis of virus
titers by a standard assay to determine the tissue culture infectious dose (TCID)
in wells with MDCK cells and analysis of the levels of cytopathic effect after 96 h
and by hemagglutination of ChRBC. The supernatants were further assayed for
anti-PR8 IgA antibodies by ELISA, as described above.
RESULTS
Synthesis of -Gal epitopes on PR8 virus. At a concentra-
tion of 100 g/ml, the virus was incubated with 30 g/ml of
recombinant 1,3GT and 1 mM UDP-Gal (UDP-galactose) as
a sugar donor. This enzyme transfers galactose from UDP-Gal
and links it as Gal1–3 to the N-acetyllactosamines (Gal1-
4GlcNAc-R) of the multiple HA carbohydrate chains to gen-
erate -Gal epitopes by a reaction that is identical to that
naturally occurring within the Golgi apparatus of nonprimate
mammalian cells (Fig. 1A). The presence of de novo synthe-
sized -Gal epitopes on PR8 could be demonstrated by West-
ern blotting (Fig. 1B) with mouse serum anti-Gal and mono-
clonal anti-Gal (M86) (14) and by ELISA with this monoclonal
anti-Gal (Fig. 1C).
Separation of PR8 proteins by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis under reducing conditions dem-
onstrates the distinct band of HA1 (60 kDa) and other viral
proteins in the range of 20 to 40 kDa. Blotting of the proteins,
followed by staining with anti-Gal from mouse sera or with the
monoclonal anti-Gal antibody M86, demonstrated the distinct
staining of the HA1 band in PR8gal but not in the same band
of the unprocessed PR8 virus (Fig. 1B). The binding of these
antibodies is highly specific and was not observed with other
proteins of the PR8gal virus or with any of the proteins of PR8
virus. It is not clear whether -Gal epitopes were expressed on
carbohydrate chains of HA2 and envelope neuraminidase,
since anti-Gal binding was too weak to determine distinct ex-
pression. These findings suggest that the synthesis of -Gal
epitopes by recombinant 1,3GT occurs primarily on the car-
bohydrate chains of HA1.
Expression of -Gal epitopes on PR8gal could be demon-
strated on the intact virus by ELISA with monoclonal anti-Gal.
This antibody bound to PR8gal as a solid-phase antigen in
ELISA wells but not to unprocessed PR8 virus or to PR8 virus
incubated with inactivated recombinant 1,3GT and UDP-Gal
(Fig. 1C). Since some influenza virus vaccines include inacti-
vation of the virus by formalin, it was of interest to determine
whether formalin treatment affects -Gal epitope expression
on the virus. Thus, ELISA was performed in parallel with
solid-phase PR8 virus that was incubated for 20 h with 0.2%
formalin (i.e., a fourfold-higher concentration than that used
for vaccine preparation). Monoclonal anti-Gal binding to for-
malin-treated PR8gal was identical to binding to untreated
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PR8gal, as shown in Fig. 1C. This was to be expected, since
formalin does not interact with carbohydrate chains. These
data imply that -Gal epitope expression on the vaccine virus
is not affected by formalin-mediated inactivation of the virus.
ELISPOT analyses of T-cell responses in mice immunized
with PR8gal or PR8. We hypothesized that vaccination of
1,3GT KO mice with inactivated PR8gal virus would result in
opsonization of the vaccinating virus by anti-Gal and the sub-
sequent targeting of this vaccine virus to APC by the antibody
(see Fig. 7). This, in turn, would result in increased transport of
the virus to lymph nodes draining the vaccination site and the
processing and presentation of immunogenic viral peptides,
ultimately resulting in a higher level of activation of virus-
specific T cells than that following vaccination with the unproc-
essed PR8 virus, which lacks -Gal epitopes. The KO mice
used in our studies were immunized three to four times with 50
mg of pig kidney membrane homogenate in order to elicit
anti-Gal production at titers similar to those found naturally in
humans. The studies below (Fig. 2 to 5) describe data obtained
from the same six PR8gal-immunized mice and six PR8-immu-
nized mice. The data on antibody production and ELISPOT
assays are representative of 15 mice per group, with similar results
for increased responses in 66% of mice immunized with
PR8gal. However, since analysis of ICS was performed for only
six of the mice in each group, the data for these six mice are
presented in Fig. 2 to 5 for comparison of the various types of
immune responses.
KO mice, which were confirmed to produce anti-Gal by
ELISA with synthetic -Gal epitopes linked to BSA (1), were
immunized subcutaneously twice at 2-week intervals with 1 g
FIG. 1. Synthesis of -Gal epitopes on influenza virus HA. (A) Illustration of enzymatic synthesis. -Gal epitopes (Gal1-3Gal1-4GlcNAc-R)
were synthesized on the N (Asn)-linked carbohydrate chains on HA by the linking of galactosyls (Gal) from the sugar donor, UDP-GAL, to
N-acetyllactosamine (Gal1-4GlcNAc-R) residues as a result of the catalytic activity of recombinant 1,3GT. (B) Expression of -Gal epitopes on
PR8gal, as shown by Western blots stained with serum anti-Gal purified from KO mouse serum and with monoclonal anti-Gal M86. Note that both
anti-Gal antibodies bind only to HA1 from PR8gal and not to the HA1 from unprocessed PR8. (C) -Gal epitope expression levels on PR8gal
virus attached to ELISA wells and studied for binding of the monoclonal anti-Gal M86. PR8gal virus treated with 0.2% formalin for 20 h had the
same level of binding as PR8gal virus generated by incubation of PR8 with active recombinant 1,3GT. The data shown are representative of three
independent experiments with similar results. ‚, unprocessed PR8 virus; ▫, PR8 virus incubated with inactivated recombinant 1,3GT; E, PR8gal
virus generated by incubation of PR8 with active recombinant 1,3GT.
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of inactivated PR8gal (corresponding to 400 HAU prior to
inactivation) or with a similar amount of inactivated PR8 lack-
ing -Gal epitopes. The vaccines were delivered in Ribi adju-
vant. The mice were studied for anti-PR8 cellular immune
responses 14 days after the second immunization. PR8-specific
T cells were identified in spleen lymphocyte populations of the
immunized mice by ELISPOT assays. For these assays, the
lymphocytes were coincubated with cells of the dendritic cell
line DC2.4 that were prepulsed for 24 h with inactivated PR8
virus. The number of T cells that secreted IFN- in the absence
of PR8 did not exceed 80 per 106 lymphocytes in any of the
mice tested (Fig. 2). In mice immunized twice with the inacti-
vated unprocessed PR8 virus (mice no. 7 to no. 12), the num-
ber of activated virus-specific T cells ranged between 400 and
700 per 106 lymphocytes, with an average	 standard deviation
of 510	 103. The number of PR8-specific T cells in four of the
six mice immunized with PR8gal (mice no. 1 to no. 4) was
severalfold higher and ranged between 1,650 and 2,510 per 106
lymphocytes. In the remaining two mice (mice no. 5 and no. 6),
the number of these T cells was 750 and 1,200 per 106 lym-
phocytes (Fig. 2). As shown below, the humoral immune re-
sponse in these two mice was also lower than in the four mice
with higher ELISPOT values. The average 	 standard devia-
tions of the ELISPOT values for the mice immunized with
PR8gal were 1,805 	 760.
Analysis of PR8-specific CD8 and CD4 T-cell responses
by ICS. In order to determine whether the virus-specific T cells
of mice immunized with PR8 or PR8gal included both CD8

T cells (i.e., precursors of CTL) and CD4 T cells (Th1 helper
T cells) specific for PR8, we performed ICS assays. This stain-
ing assay aims to detect IFN- production in activated T cells
that are also stained with CD8- or CD4-specific antibodies.
The spleen lymphocytes were coincubated for 24 h with cells of
the dendritic cell line DC2.4 prepulsed with inactivated PR8 or
with control nonpulsed DC2.4 cells. Lymphocytes incubated
with these control APC that were not pulsed, displayed no
significant ICS (
0.1%; data not shown). As shown in Fig. 3A,
2.6 to 4.4% of CD8 T cells from the six PR8-immunized mice
(mice no. 7 to no. 12) were primed in vivo by PR8 peptides and
thus were activated in vitro by the viral peptides presented on
DC2.4 cells. In contrast, in the four mice immunized with
PR8gal (mice no. 1 to no. 4) as many as 19.5 to 23.3% of CD8

T cells were activated by the process and presented PR8 pep-
tides. However, the two mice (no. 5 and no. 6) for which
ELISPOT values were lower than those for the other four mice
(Fig. 2) also had low numbers of IFN--producing CD8 T
cells, similar to mice immunized with PR8.
The differential response of T cells to the PR8 peptides
presented by DC was also observed among CD4 T cells. For
four of the mice immunized with PR8gal (mice no. 1 to no. 4),
12 to 13.7% of CD4 T cells were activated, whereas no sig-
nificant activation of CD4 T cells from the six PR8-immu-
nized mice (mice no. 7 to no. 12) was observed (Fig. 3B).
CD4 cells activated to produce IFN- represent the PR8-
specific Th1 population. The two PR8gal-immunized mice
(mice no. 5 and no. 6) with low levels of CD8 activation also
had very low levels of CD4 activation, implying that in these
mice there was no measurable increase in the antivirus cellular
immune response, as determined by ICS and ELISPOT assays.
Note that the very high number of activated T cells in both the
CD8 and CD4 populations of PR8gal-immunized mice are
unusually high for ICS assays, for which the response to a
defined immunogenic peptide is only one to a few percent. The
10% response of CD8 and CD4 T cells of mice no. 1 to no.
4 in Fig. 3 is likely to reflect the immune response to multiple
immunogenic viral peptides of the various proteins comprising
the immunizing PR8gal influenza virus. Also note that the low
immune response in two of the six PR8gal-immunized mice is
not associated with low levels of anti-Gal response, since all the
mice were found to produce anti-Gal at titers comparable to
those in humans (data not shown).
Production of anti-PR8 antibodies in immunized mice. The
sera from KO mice immunized with PR8 or PR8gal were
assayed for production of antibodies to the unprocessed PR8
virus used as a solid-phase antigen in ELISA (Fig. 4A). The
levels of anti-PR8 IgG antibody activities in the six mice im-
munized with PR8gal were much higher than those in PR8-
immunized mice. Four mice immunized with PR8gal had very
high anti-PR8-antibody activity (mice no. 1 to no. 4), as indi-
cated by an average of 50% maximum binding (i.e., 1.5 optical
density) at a serum dilution of 1:102,400. Even mice no. 5 and
no. 6 (mice displaying low levels of CD4 and CD8 activa-
tion) (Fig. 2 and 3) displayed 50% of the maximum anti-PR8
IgG activity at serum dilutions of 1:12,800 and 1:6,400, respec-
tively. In contrast, for mice immunized with PR8 (mice no. 7 to
no. 12) (Fig. 2 and 3), 50% of the maximum binding level was
observed at a serum dilution of 1:400 (i.e., 200-fold lower
than for PR8gal-immunized mice no. 1 to no. 4).
The association between the high levels of anti-PR8 anti-
body response and anti-Gal-mediated targeting of the vacci-
nating virus can be further inferred from the data obtained
with C57BL/6 WT mice. These mice express -Gal epitopes on
their cells and thus cannot produce anti-Gal, despite four im-
munizations with pig kidney membranes (1, 39). Repeating the
FIG. 2. Analysis by ELISPOT assay of IFN- secretion levels in
mice immunized with PR8 or PR8gal. Lymphocytes from six mice
immunized with inactivated PR8gal virus (#1 to #6) or inactivated
PR8 (#7 to #12) were obtained 14 days after the second immunization
and incubated with cells of the dendritic cell line DC2.4, prepulsed
with inactivated PR8, and subjected to ELISPOT (hatched columns).
Data for lymphocytes incubated with DC that were not prepulsed with
PR8 are presented as empty columns. The data are presented as
means 	 standard deviations of the results for triplicate wells.
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immunization studies with PR8 or PR8gal with these WT mice
resulted in no significant differences in anti-PR8 antibody re-
sponses between the two groups (Fig. 4B). Thus, in the absence
of anti-Gal, the expression of -Gal epitopes on the immuniz-
ing virus has no effect on the immunogenicity of the virus.
The differential humoral immune response in KO mice im-
munized with PR8gal versus those immunized with PR8 was
also evident in analyses of anti-PR8 IgA antibodies. The sig-
nificance of this immunoglobulin class is primarily in mucosal
immunity, which prevents viral infection of respiratory tract
cells. As shown in Fig. 4C, for mice no. 1 to no. 4 anti-PR8 IgA
activity was 50- to 100-fold higher in PR8-immunized mice no.
7 to no. 12. This increased antibody response was indicated by
the finding that anti-PR8 antibody activity in serum dilutions of
1:50 for mice no. 7 to no. 12 was similar to the activity in serum
dilutions of 1:3,200 to 1:6,400 for mice no. 1 to no. 4.
Inhibition of hemagglutinating antibodies in immunized
mice. One of the distinct antibody activities that protects against
infection by the influenza virus is that of antibodies binding to the
HA of the infectious virus, indicated by the prevention of subse-
quent binding of this envelope glycoprotein to target cells for
infection. The activity of these antibodies can be determined by
the inhibition of hemagglutination of ChRBC by the PR8 virus, as
determined by assays at virus concentrations of 5 HAU/ml. The
virus was incubated with 50 l of sera at twofold serial dilutions,
starting at a dilution of 1:10. After 24 h at 4°C, 50 l of 1%
ChRBC was added, and HI was scored after 30 min. As shown in
Fig. 5, the levels of HI activity in PR8gal-immunized KO mice
was many times higher than that in PR8-immunized mice. The
average HI titer in the former group was 1:135, whereas in the
latter group it was 1:15, i.e., ninefold lower. Two mice (no. 5 and
no. 6) among the PR8gal-immunized mice displayed a much
lower level of HI activity, in agreement with the other parameter
of low levels of anti-influenza virus cellular and humoral immune
responses shown in Fig. 2 to 4. The average level of HI activity in
the highly responsive mice in that group (no. 1 to no. 4) is 1:180,
which is 12-fold higher than in the control group immunized with
unmodified PR8 (Fig. 5).
Induction of a protective immune response against chal-
lenge with PR8. KO mice immunized with heat-inactivated
FIG. 3. Intracellular staining of IFN- in CD8 (A) and CD4 (B) T cells in PR8gal- or PR8-immunized mice. ICS analysis of levels of CD8

(A, including two left panels) and CD4 (B, including two right panels) T cells in PR8gal (mice no. 1 to 6)- or PR8 (mice no. 7 to 12)-immunized
mice. Lymphocytes were obtained as described in the legend to Fig. 2 and four-color stained for CD3, CD8, CD4 membrane marker, and
intracellular IFN-. Gated CD3/CD8- or CD3/CD4-positive events were analyzed for IFN- production. The percentage of CD8 or CD4
T cells with intracellular IFN- is indicated in the upper right quadrant for each mouse. Note that four of the six mice immunized with PR8gal
(#1 to #4) had much higher proportions of IFN--producing CD8 and CD4 T cells than mice immunized with PR8.
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PR8 or PR8gal virus (25 mice/group) were studied for resis-
tance to intranasal challenge with 2,000 PFU of live PR8 virus.
The mice were subsequently monitored for survival for a pe-
riod of 30 days. Immunization of the mice with inactivated PR8
virus did not confer significant protection against challenge
with PR8 (Fig. 6A). By day 10 postchallenge, 89% of the mice
had died of the infection. In contrast, mice immunized with
inactivated PR8gal virus were much more resistant to the
challenge. Only 11% of the mice succumbed to the viral infec-
tion, and the remaining 89% survived. Survival data for day 30
were the same as for day 15, as shown in Fig. 6A. These results
strongly suggest that the increased cellular and humoral im-
mune responses in PR8gal-immunized mice, shown in Fig. 2 to
5, correlate with increased resistance to infection by the PR8
virus.
In order to further study this protective immune response,
the immunizations were repeated for five mice per group. The
mice were euthanized 3 days after intranasal challenge, and
their lungs were harvested and homogenized in PBS to a total
volume of 1 ml. The virus titers in supernatants of the homog-
enate were determined by measuring the TCID in MDCK cell
monolayers (i.e., the highest dilution resulting in a cytopathic
effect on MDCK cells) and the hemagglutination of ChRBC.
Incubation of the virus at serial 10-fold dilutions with MDCK
cells for 96 h indicated that two of the PR8gal-immunized
mice had TCIDs of 100 and the remaining three mice had
TCIDs of 10; i.e., the lung supernatant dilution of 1:10 was the
highest dilution resulting in a cytopathic effect on MDCK cells
(Fig. 6B). In contrast, four of the five PR8-immunized mice
had TCIDs of 1,000, and only one had a TCID of 100. The
average TCID among the PR8gal-immunized mice was 18-
fold lower than that in PR8-immunized mice. This difference in
the presence of live PR8 in the lungs of the PR8-challenged
mice was confirmed by analysis of the hemagglutination titers
with ChRBC. As shown in Fig. 6C, incubation of lung homoge-
nate supernatants from PR8gal-immunized mice with ChRBC
resulted in hemagglutination titers (reciprocal of end point
dilution displaying agglutination) of 50 for four mice and 100
for one mouse. In contrast, the titer for three of the PR8-
immunized mice was 1,000, and for the remaining two mice it
was 10,000.
One of the factors preventing virus infection and subsequent
FIG. 4. Production of anti-PR8 antibodies in mice immunized
twice with 1 g inactivated PR8gal (F) or with inactivated PR8 (E) in
Ribi adjuvant and measured by ELISA with PR8 virus as a solid-phase
antigen. (A) Anti-PR8 IgG response in KO mice. (B) Anti-PR8 IgG
response in WT mice. (C) Anti-PR8 IgA response in KO mice (n  6
per group). The two KO mice in panels A and C with the lowest levels
of response (F) are mice no. 5 and 6 in Fig. 2 and 3 above.
FIG. 5. HI activity in KO mice immunized with PR8gal or PR8.
Results are presented as reciprocals of the serum dilutions that displayed
HI activity. Note that the levels of HI activity in mice immunized twice
with 1 g PR8gal is much higher than that in the sera of mice immunized
with 1 g PR8 (with the exception of mice no. 5 and 6).
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virus production in the lung cells of the PR8gal-immunized
mice is likely the anti-PR8 IgA antibody activity in the lungs.
The activity of these antibodies was determined by ELISA,
using serial twofold dilutions of the lung homogenate super-
natants (Fig. 4C). As shown in Fig. 6D, the lung homogenates
from PR8-immunized mice contained no detectable anti-PR8
IgA antibodies, whereas those from all five PR8gal-immunized
mice had distinct anti-PR8 IgA activity. The lack of detectable
anti-PR8 IgA antibodies in the lungs of PR8-immunized mice
corresponds to the low level of such antibodies in the sera of
PR8-immunized mice (Fig. 4C) and suggests that the level of
these antibodies in the lungs is beneath the detection level for
ELISA.
DISCUSSION
The present study demonstrates a method for increasing the
immunogenicity of inactivated influenza virus vaccines by syn-
thesizing -Gal epitopes on the multiple N-linked carbohy-
drate chains on envelope glycoproteins of the virus. Injection
of inactivated PR8 virus expressing -Gal epitopes resulted in
opsonization by anti-Gal, which in turn targeted the vaccinat-
ing virus to APC. This mechanism is illustrated in Fig. 7. The
suboptimal uptake of vaccines that lack markers for recogni-
tion by APC at the vaccination site is a major limiting factor in
their immunogenicity. The present study indicates that anti-
Gal-mediated opsonization of the inactivated PR8gal virus
FIG. 6. Survival rates and analyses of lungs from mice immunized twice with inactivated PR8 or PR8gal and receiving intranasal challenge with live
PR8. (A) PR8 (E)- or PR8gal (F)-immunized mice were challenged with 2,000 PFU of live PR8 in 50-l solutions (n  25/group). Survival data are
presented as percentages of live mice at different time points postchallenge. The survival data for day 30 were similar to those for day 15 postchallenge.
(B) Analysis of virus titers as the TCID in lungs of immunized mice 3 days postchallenge (n  5/group). The supernatants of lung homogenates
were incubated in serial 10-fold dilutions in 96-well plates with MDCK cell monolayers. The levels of cytopathic effects were scored after 96 h. (C) Analysis
of virus titer by hemagglutination in lungs of immunized mice 3 days postchallenge (n  5/group). (D) Levels of anti-PR8 IgA antibodies in lungs of
immunized mice 3 days post challenge (n  5/group). F, PR8gal-immunized mice; E, PR8-immunized mice (n  5 mice/group).
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vaccine leads to a marked increase in the cellular immune
response. This was shown for four of six PR8gal-immunized
mice, for which the numbers of PR8-specific CD8 and CD4
T cells were many times higher than those in PR8-immunized
mice (Fig. 2 and 3). Accordingly, the level of anti-PR8 antibody
response in the four high responder PR8gal-immunized mice
was 200-fold higher than that for PR8-immunized mice. The
increased immune response in PR8gal-immunized mice cor-
related with marked resistance to respiratory tract infection
with live PR8 virus: 90% of PR8gal-immunized mice versus
10% of PR8 immunized mice survived. The present study is
the first to demonstrate protection against challenge with a live
virus following immunization with an inactivated virus engi-
neered to express -Gal epitopes. The increased resistance of
PR8gal-immunized mice was also demonstrated by the lower
numbers of infectious virus in the lungs of the challenged mice,
as assayed 3 days postchallenge.
In previous studies, we demonstrated the increased in vitro
uptake of anti-Gal-opsonized PR8 by APC (18). In those stud-
ies, expression of -Gal epitopes on PR8 was achieved by
propagating the virus in MDBK (Madin-Darby bovine kidney)
and MDCK cells. The endogenous 1,3GT activity in these
bovine and canine cells resulted in synthesis of -Gal epitopes
on a portion of the carbohydrate chains on viral envelope
glycoproteins transported through the Golgi apparatus. In
vitro opsonization of such inactivated PR8 virus by anti-Gal
resulted in increased uptake by APC, as indicated by an 10-
fold increase in the subsequent activation of an HA-specific
T-cell clone by processed peptides presented on the APC,
compared to the level of activation of these HA-specific T cells
in the absence of anti-Gal (18). These in vitro data support the
results of the present study, which indicate that this increased
uptake by APC results in increased immunogenicity.
The in vitro synthesis of -Gal epitopes by recombinant
1,3GT demonstrated in the present study is preferable to
synthesis by propagation in MDBK or MDCK cells, because
the intracellular synthesis of -Gal epitopes on PR8 is subop-
timal, as many of the carbohydrate chains are capped with
sialic acid, due to the catalytic activity of sialyltransferase. This
enzyme shares a compartment with 1,3GT within the trans-
Golgi apparatus; thus, the two enzymes compete with each
other for the capping of the carbohydrate chains on glycocon-
jugates passing through the Golgi apparatus (38). In order to
maximize the number of -Gal epitopes on the influenza viri-
FIG. 7. Anti-Gal-mediated targeting of vaccinating PR8gal virus to APC. Inactivated PR8gal virus with -Gal epitopes (red diamonds) was
injected as a vaccine. Anti-Gal binds to the -Gal epitopes on the virus and opsonizes it. The Fc portion of anti-Gal interacts with FcR on APC
and induces uptake of the vaccine by the APC. The internalized virus undergoes processing in the endocytic vesicles and the cytoplasm. The viral
immunogenic peptides are presented on MHC class I molecules for activation of CD8 CTL precursors (Tc cells) and on MHC class II molecules
for activation of helper T cells (Th cells). Signal 2 provided by the APC also facilitates this activation. Activated Th cells provide help for the
antibody response by B cells and for CTL activation. Activated Tc cells differentiate into CTL, which kill virus-infected cells. TCR, T-cell receptor.
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ons, the virus can be incubated in vitro with 1,3GT and
UDP-Gal. In previous studies on the synthesis of -Gal
epitopes on PR8 with radiolabeled UDP-Gal, we estimated
that the de novo expression of -Gal epitopes is 3,000 per
virion (22). Thus, a high concentration of -Gal epitopes on
PR8gal is likely to result in the binding of many anti-Gal IgG
molecules that will effectively target the vaccine virions to APC
at the vaccination site.
Our Western blot immunostaining studies (Fig. 1B) sug-
gested that most of the -Gal epitopes synthesized on PR8
incubated with 1,3GT are present on the carbohydrate chains
of HA. These findings are particularly significant for formulat-
ing treatment plans to use inactivated virus or recombinant HA
vaccines for future pandemics of highly virulent viruses such as
H5N1 avian influenza virus converted into a form which is
transmitted from human to human. Based on GenBank se-
quences, H5-HA, like H1-HA, carries carbohydrate chains at
six to eight N-glycosylation sites. Our data suggest that influ-
enza virus vaccines comprised of PR8 virus containing the
HA-H5 gene of avian influenza virus and processed to express
-Gal epitopes are likely to be much more immunogenic than
the same unprocessed vaccine lacking this epitope.
Expression of -Gal epitopes on recombinant HA-H5 pro-
duced in CHO cells may also significantly increase the immu-
nogenicity of such a recombinant vaccine that will be risk free
for vaccinees. The immunogenicity of recombinant protein
vaccines lacking -Gal epitopes may be suboptimal because of
limited uptake by APC at the vaccination site. Synthesis of
-Gal epitopes on the carbohydrate chains of recombinant
H5-HA produced in CHO cells can be achieved by the reaction
used in the present study. -Gal epitope synthesis on the re-
combinant glycoprotein also requires the addition of neur-
aminidase to remove sialic acid, as we previously performed
with gp120 (1). As a result of such an enzymatic reaction, all
the complex carbohydrate chains on recombinant gp120 were
capped with -Gal epitopes to generate gp120gal. Our in vivo
studies with recombinant gp120gal demonstrated a 100-fold
increase in immunogenicity due to anti-Gal-mediated targeting
of the vaccine recombinant protein to APC in KO mice (1).
Similar studies with recombinant HA expressing -Gal
epitopes will enable us to determine the extent of increased
immunogenicity of this recombinant protein and its ability to
confer protection against challenge with live PR8 virus. If suc-
cessful, such studies will indicate that expression of -Gal
epitopes on recombinant envelope proteins is likely to offer an
effective alternative to inactivated virus vaccines.
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